micafungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antifungal antibiotics	1798	235114-32-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mycamine micafungin micafungin sodium FK-463 FK463	A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS. Molecular weight: 1270.28 Formula: C56H71N9O23S CLOGP: -1.99 LIPINSKI: 3 HAC: 32 HDO: 16 TPSA: 510.14 ALOGS: -3.77 ROTB: 18

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mycamine
micafungin
micafungin sodium
FK-463
FK463

A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.

Molecular weight: 1270.28
Formula: C56H71N9O23S
CLOGP: -1.99
LIPINSKI: 3
HAC: 32
HDO: 16
TPSA: 510.14
ALOGS: -3.77
ROTB: 18

Drug dosage:

Dose	Unit	Route
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.17 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	16 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
April 25, 2008	EMA	Astellas Pharma Europe B.V.
March 16, 2005	FDA	FUJISAWA HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	299.04	26.72	181	7283	118268	63363290
Pre-engraftment immune reaction	172.45	26.72	29	7435	209	63481349
Human herpesvirus 6 infection	159.82	26.72	42	7422	2915	63478643
Encephalitis viral	145.42	26.72	35	7429	1697	63479861
Aplastic anaemia	141.00	26.72	50	7414	9519	63472039
Multiple organ dysfunction syndrome	135.84	26.72	84	7380	56668	63424890
Pneumonia fungal	117.84	26.72	38	7426	5417	63476141
Acute graft versus host disease	108.69	26.72	34	7430	4394	63477164
Cytomegalovirus test positive	103.54	26.72	30	7434	2988	63478570
Sepsis	102.25	26.72	107	7357	153016	63328542
Bacterial sepsis	87.24	26.72	28	7436	3930	63477628
Mucormycosis	83.00	26.72	25	7439	2846	63478712
Acute graft versus host disease in skin	82.61	26.72	26	7438	3426	63478132
Septic shock	78.48	26.72	64	7400	66565	63414993
Aspergillus infection	78.01	26.72	31	7433	8062	63473496
Hepatic function abnormal	73.98	26.72	49	7415	37093	63444465
Cytomegalovirus viraemia	70.06	26.72	26	7438	5623	63475935
Gastrointestinal fungal infection	67.67	26.72	14	7450	336	63481222
Cytomegalovirus infection	65.79	26.72	37	7427	20915	63460643
Thrombotic microangiopathy	63.67	26.72	29	7435	10532	63471026
Engraft failure	61.30	26.72	13	7451	353	63481205
Sinus polyp	59.98	26.72	13	7451	392	63481166
Off label use	59.76	26.72	194	7270	674268	62807290
Bronchopulmonary aspergillosis	59.38	26.72	26	7438	8609	63472949
Haemophagocytic lymphohistiocytosis	57.27	26.72	27	7437	10600	63470958
Enterococcal sepsis	57.21	26.72	16	7448	1402	63480156
Pathogen resistance	56.45	26.72	23	7441	6375	63475183
Respiratory failure	55.43	26.72	64	7400	101794	63379764
Systemic mycosis	55.19	26.72	15	7449	1182	63480376
Meningoencephalitis herpetic	54.86	26.72	15	7449	1209	63480349
Aspartate aminotransferase increased	54.71	26.72	60	7404	90217	63391341
Liver abscess	54.04	26.72	18	7446	2836	63478722
Graft versus host disease	51.87	26.72	22	7442	6741	63474817
Fungal infection	51.09	26.72	39	7425	36835	63444723
Nasal abscess	50.61	26.72	10	7454	189	63481369
Pyrexia	50.60	26.72	145	7319	470333	63011225
Fungaemia	48.89	26.72	16	7448	2387	63479171
Fatigue	48.60	26.72	22	7442	888006	62593552
Weissella infection	47.72	26.72	7	7457	17	63481541
Product use in unapproved indication	46.75	26.72	79	7385	179001	63302557
Plasma cell leukaemia	46.73	26.72	13	7451	1117	63480441
Acute myeloid leukaemia recurrent	46.34	26.72	14	7450	1609	63479949
Arthralgia	44.41	26.72	7	7457	569703	62911855
Systemic candida	44.18	26.72	16	7448	3229	63478329
Platelet count decreased	44.12	26.72	61	7403	116061	63365497
Alanine aminotransferase increased	43.21	26.72	57	7407	103713	63377845
Mucosal erosion	42.96	26.72	13	7451	1503	63480055
Encephalitis fungal	42.59	26.72	7	7457	43	63481515
Disseminated intravascular coagulation	42.50	26.72	27	7437	19024	63462534
Enterobacter infection	41.98	26.72	14	7450	2213	63479345
Cytokine release syndrome	41.50	26.72	24	7440	14290	63467268
Biloma	40.54	26.72	7	7457	60	63481498
Hypoalbuminaemia	40.21	26.72	22	7442	11783	63469775
Pain	37.96	26.72	20	7444	740608	62740950
Oral fungal infection	37.50	26.72	14	7450	3077	63478481
Fungal oesophagitis	37.49	26.72	10	7454	734	63480824
Chronic graft versus host disease	37.45	26.72	14	7450	3088	63478470
Enterococcal infection	36.42	26.72	18	7446	7830	63473728
Epstein-Barr virus associated lymphoproliferative disorder	36.08	26.72	12	7452	1882	63479676
Trichosporon infection	35.65	26.72	8	7456	284	63481274
Varicella zoster virus infection	35.64	26.72	13	7451	2676	63478882
Encephalitis Japanese B	35.46	26.72	6	7458	45	63481513
Neutropenia	35.23	26.72	69	7395	174936	63306622
Drug ineffective	34.74	26.72	225	7239	1044540	62437018
Pulmonary mucormycosis	34.60	26.72	8	7456	325	63481233
Drug ineffective for unapproved indication	34.46	26.72	30	7434	34033	63447525
Pulmonary trichosporonosis	34.29	26.72	6	7458	56	63481502
Acute respiratory distress syndrome	32.83	26.72	25	7439	23509	63458049
Fungal sepsis	32.20	26.72	10	7454	1260	63480298
Mucosal inflammation	31.59	26.72	33	7431	46895	63434663
Renal impairment	31.44	26.72	45	7419	88310	63393248
Acute lymphocytic leukaemia recurrent	30.19	26.72	11	7453	2258	63479300
Fall	30.13	26.72	5	7459	392329	63089229
Staphylococcal sepsis	30.06	26.72	16	7448	8112	63473446
Cryptosporidiosis infection	29.65	26.72	7	7457	312	63481246
Pleural effusion	29.60	26.72	45	7419	93165	63388393
Agranulocytosis	29.26	26.72	24	7440	25110	63456448
Acute graft versus host disease in intestine	29.06	26.72	10	7454	1739	63479819
Alopecia	29.03	26.72	3	7461	337533	63144025
Aspergillus test positive	28.96	26.72	7	7457	345	63481213
Malaise	28.41	26.72	7	7457	415947	63065611
Mucosal disorder	26.95	26.72	10	7454	2159	63479399
Drug resistance	26.90	26.72	22	7442	22911	63458647
Candida infection	26.74	26.72	24	7440	28327	63453231

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	222.02	21.24	94	12106	9622	34935109
Febrile neutropenia	200.02	21.24	242	11958	136607	34808124
Acute graft versus host disease in skin	148.35	21.24	59	12141	5142	34939589
Multiple organ dysfunction syndrome	146.65	21.24	156	12044	76410	34868321
Cytomegalovirus viraemia	128.08	21.24	59	12141	7371	34937360
Aspergillus infection	113.59	21.24	64	12136	12190	34932541
Bronchopulmonary aspergillosis	105.49	21.24	65	12135	14594	34930137
Disseminated intravascular coagulation	95.30	21.24	71	12129	21745	34922986
Herpes simplex oesophagitis	93.34	21.24	20	12180	179	34944552
Fungal infection	93.19	21.24	62	12138	15873	34928858
Graft versus host disease	89.38	21.24	52	12148	10517	34934214
Acute graft versus host disease	85.83	21.24	43	12157	6460	34938271
Acute graft versus host disease in intestine	85.24	21.24	33	12167	2675	34942056
Lymphoid tissue hypoplasia	83.52	21.24	21	12179	397	34944334
Thymus hypoplasia	83.52	21.24	21	12179	397	34944334
Candida infection	82.66	21.24	60	12140	17655	34927076
Product use in unapproved indication	80.86	21.24	146	12054	117353	34827378
Trichosporon infection	71.81	21.24	21	12179	713	34944018
Disseminated aspergillosis	70.55	21.24	21	12179	759	34943972
Venoocclusive liver disease	69.49	21.24	40	12160	7926	34936805
Cytomegalovirus test positive	67.40	21.24	31	12169	3855	34940876
Pyrexia	67.25	21.24	261	11939	332752	34611979
Fusarium infection	66.32	21.24	22	12178	1138	34943593
Fungaemia	65.87	21.24	27	12173	2541	34942190
Cystitis haemorrhagic	64.66	21.24	34	12166	5645	34939086
Respiratory failure	63.61	21.24	126	12074	108446	34836285
Mucormycosis	63.21	21.24	34	12166	5908	34938823
Mucosal inflammation	60.58	21.24	71	12129	38551	34906180
Sepsis	58.53	21.24	158	12042	166403	34778328
Fatigue	57.41	21.24	29	12171	370624	34574107
Acute myeloid leukaemia recurrent	52.89	21.24	22	12178	2148	34942583
Acute graft versus host disease in liver	52.56	21.24	20	12180	1546	34943185
Drug ineffective	52.53	21.24	304	11896	456447	34488284
Pre-engraftment immune reaction	52.44	21.24	11	12189	88	34944643
Septic shock	51.57	21.24	91	12109	71743	34872988
Cytomegalovirus infection	51.24	21.24	54	12146	26081	34918650
Systemic candida	50.23	21.24	25	12175	3701	34941030
Cytokine release syndrome	47.96	21.24	49	12151	22828	34921903
Glomerulosclerosis	44.45	21.24	15	12185	818	34943913
Dizziness	44.14	21.24	11	12189	218510	34726221
Hepatic function abnormal	43.84	21.24	65	12135	44298	34900433
Human herpesvirus 6 infection	43.76	21.24	19	12181	2062	34942669
Chronic graft versus host disease	43.67	21.24	24	12176	4349	34940382
Staphylococcal sepsis	42.88	21.24	32	12168	9812	34934919
Enterococcal infection	42.22	21.24	31	12169	9275	34935456
Systemic mycosis	41.92	21.24	17	12183	1556	34943175
Botulism	41.28	21.24	10	12190	161	34944570
Tumour lysis syndrome	40.30	21.24	39	12161	17020	34927711
Off label use	39.22	21.24	265	11935	419259	34525472
Encephalitis viral	38.96	21.24	15	12185	1197	34943534
Geotrichum infection	38.86	21.24	12	12188	492	34944239
Fall	37.65	21.24	12	12188	202873	34741858
Enterococcus test positive	37.13	21.24	14	12186	1055	34943676
Haemophagocytic lymphohistiocytosis	37.11	21.24	33	12167	12940	34931791
Candida sepsis	34.69	21.24	14	12186	1265	34943466
Device related sepsis	33.74	21.24	18	12182	3075	34941656
Fungal endocarditis	33.37	21.24	10	12190	370	34944361
Hypogonadism	32.99	21.24	16	12184	2239	34942492
Bacterial infection	32.98	21.24	35	12165	17028	34927703
Immunosuppressant drug level increased	31.67	21.24	22	12178	6033	34938698
Drug resistance	31.57	21.24	42	12158	25885	34918846
Myocardial infarction	31.39	21.24	3	12197	121082	34823649
Acute myeloid leukaemia	31.01	21.24	35	12165	18235	34926496
Product dose omission issue	30.94	21.24	3	12197	119708	34825023
Graft versus host disease in gastrointestinal tract	30.81	21.24	18	12182	3665	34941066
Bacteraemia	30.49	21.24	36	12164	19681	34925050
Disseminated cryptococcosis	30.28	21.24	13	12187	1373	34943358
Kidney fibrosis	30.18	21.24	15	12185	2213	34942518
Clostridium difficile colitis	29.93	21.24	32	12168	15698	34929033
Cerebral aspergillosis	29.87	21.24	13	12187	1419	34943312
Pseudomembranous colitis	29.77	21.24	16	12184	2775	34941956
Cystitis viral	29.64	21.24	10	12190	545	34944186
Necrotising oesophagitis	29.45	21.24	10	12190	556	34944175
Cholestatic liver injury	29.34	21.24	15	12185	2349	34942382
Sinusitis fungal	29.24	21.24	10	12190	568	34944163
Pneumonia fungal	28.53	21.24	22	12178	7078	34937653
Platelet count decreased	28.32	21.24	99	12101	119618	34825113
Blood beta-D-glucan increased	28.02	21.24	9	12191	420	34944311
Idiopathic pneumonia syndrome	27.63	21.24	8	12192	262	34944469
Mucosal disorder	27.54	21.24	13	12187	1713	34943018
Aspartate aminotransferase increased	27.54	21.24	68	12132	67715	34877016
Delayed graft function	27.30	21.24	14	12186	2207	34942524
Graft versus host disease in skin	27.20	21.24	17	12183	3908	34940823
Klebsiella infection	27.02	21.24	23	12177	8508	34936223
Engraft failure	26.90	21.24	9	12191	478	34944253
Renal failure	25.89	21.24	102	12098	130455	34814276
Somnolence	25.74	21.24	4	12196	111112	34833619
Rhinocerebral mucormycosis	25.54	21.24	9	12191	559	34944172
Drug-induced liver injury	25.30	21.24	40	12160	28792	34915939
Arthralgia	25.21	21.24	14	12186	170027	34774704
Infection	24.89	21.24	79	12121	90836	34853895
Enterococcal sepsis	24.87	21.24	12	12188	1660	34943071
Functional gastrointestinal disorder	24.38	21.24	13	12187	2218	34942513
Infection in an immunocompromised host	24.10	21.24	9	12191	660	34944071
Weight decreased	24.06	21.24	16	12184	176285	34768446
Alanine aminotransferase increased	23.76	21.24	72	12128	80743	34863988
Pseudomonal sepsis	23.67	21.24	15	12185	3532	34941199
Depression	23.65	21.24	3	12197	97095	34847636
Ophthalmic vein thrombosis	23.62	21.24	5	12195	42	34944689
Blast cell count increased	23.18	21.24	10	12190	1068	34943663
Blood bilirubin increased	23.04	21.24	45	12155	38251	34906480
Pain in extremity	22.54	21.24	8	12192	126505	34818226
Bacterial toxaemia	22.39	21.24	6	12194	147	34944584
Lymphopenia	22.29	21.24	28	12172	16307	34928424
Pruritus	22.06	21.24	11	12189	141970	34802761
Antithrombin III decreased	21.79	21.24	7	12193	327	34944404
Reactive gastropathy	21.60	21.24	7	12193	336	34944395
Headache	21.51	21.24	23	12177	200612	34744119
Graft versus host disease in liver	21.51	21.24	10	12190	1274	34943457
Haemorrhagic necrotic pancreatitis	21.49	21.24	6	12194	172	34944559
Cerebral ventricle collapse	21.42	21.24	5	12195	68	34944663
Vascular device infection	21.41	21.24	15	12185	4170	34940561
Liver disorder	21.36	21.24	40	12160	32957	34911774

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	433.95	20.41	387	18157	230612	79495232
Aplastic anaemia	360.32	20.41	141	18403	17764	79708080
Multiple organ dysfunction syndrome	242.27	20.41	210	18334	120036	79605808
Pre-engraftment immune reaction	209.06	20.41	40	18504	301	79725543
Cytomegalovirus viraemia	196.25	20.41	83	18461	12738	79713106
Aspergillus infection	185.16	20.41	90	18454	19071	79706773
Human herpesvirus 6 infection	173.67	20.41	60	18484	5310	79720534
Encephalitis viral	167.42	20.41	49	18495	2530	79723314
Acute graft versus host disease	159.54	20.41	67	18477	10100	79715744
Sepsis	147.19	20.41	241	18303	269187	79456657
Fungal infection	145.49	20.41	101	18443	41647	79684197
Mucormycosis	140.25	20.41	58	18486	8411	79717433
Bronchopulmonary aspergillosis	138.79	20.41	78	18466	22216	79703628
Product use in unapproved indication	138.15	20.41	225	18319	250134	79475710
Acute graft versus host disease in skin	128.69	20.41	53	18491	7605	79718239
Disseminated intravascular coagulation	118.56	20.41	84	18460	35758	79690086
Cytomegalovirus infection	114.20	20.41	88	18456	42556	79683288
Pneumonia fungal	112.34	20.41	54	18490	11156	79714688
Trichosporon infection	110.98	20.41	29	18515	979	79724865
Disseminated aspergillosis	108.00	20.41	29	18515	1089	79724755
Graft versus host disease	105.71	20.41	57	18487	14969	79710875
Respiratory failure	104.35	20.41	166	18378	180745	79545099
Septic shock	103.57	20.41	135	18409	122666	79603178
Lymphoid tissue hypoplasia	103.57	20.41	27	18517	903	79724941
Hepatic function abnormal	103.39	20.41	105	18439	73002	79652842
Fungaemia	102.43	20.41	39	18505	4552	79721292
Thymus hypoplasia	102.36	20.41	27	18517	946	79724898
Pyrexia	101.72	20.41	367	18177	678342	79047502
Drug ineffective	99.03	20.41	503	18041	1080410	78645434
Cytomegalovirus test positive	96.01	20.41	40	18504	5907	79719937
Fatigue	95.23	20.41	49	18495	929678	78796166
Candida infection	93.98	20.41	75	18469	38139	79687705
Systemic candida	91.38	20.41	40	18504	6666	79719178
Herpes simplex oesophagitis	88.70	20.41	20	18524	357	79725487
Mucosal inflammation	86.44	20.41	97	18447	75483	79650361
Acute graft versus host disease in intestine	85.40	20.41	33	18511	4008	79721836
Cytokine release syndrome	85.01	20.41	69	18475	35929	79689915
Systemic mycosis	83.16	20.41	29	18515	2637	79723207
Enterococcal infection	79.48	20.41	48	18496	15612	79710232
Venoocclusive liver disease	78.21	20.41	43	18501	11728	79714116
Arthralgia	77.35	20.41	19	18525	571784	79154060
Haemophagocytic lymphohistiocytosis	76.44	20.41	53	18491	21784	79704060
Acute myeloid leukaemia recurrent	76.42	20.41	29	18515	3354	79722490
Platelet count decreased	72.88	20.41	148	18396	194516	79531328
Aspartate aminotransferase increased	67.54	20.41	118	18426	138523	79587321
Tumour lysis syndrome	65.38	20.41	50	18494	23889	79701955
Off label use	65.27	20.41	396	18148	906819	78819025
Fusarium infection	65.21	20.41	22	18522	1810	79724034
Pain	64.94	20.41	42	18502	703760	79022084
Fall	64.39	20.41	17	18527	487612	79238232
Bacterial sepsis	63.03	20.41	33	18511	8165	79717679
Dizziness	61.23	20.41	23	18521	526418	79199426
Pathogen resistance	60.27	20.41	39	18505	14303	79711541
Enterococcal sepsis	60.25	20.41	23	18521	2703	79723141
Headache	58.96	20.41	40	18504	653732	79072112
Drug resistance	58.50	20.41	60	18484	42153	79683691
Bacterial infection	57.61	20.41	52	18492	31228	79694616
Alanine aminotransferase increased	56.60	20.41	120	18424	162450	79563394
Meningoencephalitis herpetic	55.81	20.41	20	18524	1969	79723875
Staphylococcal sepsis	54.51	20.41	37	18507	14689	79711155
Cystitis haemorrhagic	54.13	20.41	31	18513	9141	79716703
Gastrointestinal fungal infection	52.60	20.41	14	18530	508	79725336
Acute graft versus host disease in liver	52.58	20.41	19	18525	1916	79723928
Joint swelling	51.95	20.41	4	18540	288642	79437202
Blood bilirubin increased	51.46	20.41	70	18474	66162	79659682
Chronic graft versus host disease	51.29	20.41	27	18517	6754	79719090
Disseminated cryptococcosis	49.80	20.41	18	18526	1816	79724028
Bacteraemia	49.79	20.41	49	18495	32775	79693069
Malaise	49.71	20.41	26	18518	489843	79236001
Acute myeloid leukaemia	48.52	20.41	47	18497	30838	79695006
Engraft failure	48.28	20.41	14	18530	699	79725145
Sinus polyp	47.50	20.41	13	18531	525	79725319
Nasopharyngitis	47.18	20.41	3	18541	253878	79471966
Hypoalbuminaemia	46.47	20.41	39	18505	21258	79704586
Product dose omission issue	45.78	20.41	3	18541	247534	79478310
Neutrophil count decreased	44.47	20.41	79	18465	93880	79631964
Candida sepsis	44.29	20.41	18	18526	2495	79723349
Thrombotic microangiopathy	44.14	20.41	37	18507	20132	79705712
Nasal abscess	44.11	20.41	10	18534	183	79725661
Pain in extremity	43.92	20.41	15	18529	364523	79361321
Klebsiella infection	43.29	20.41	33	18511	15687	79710157
Clostridium difficile colitis	43.13	20.41	45	18499	32238	79693606
Hypogonadism	43.07	20.41	16	18528	1744	79724100
Weissella infection	42.95	20.41	7	18537	17	79725827
Cerebral aspergillosis	42.76	20.41	16	18528	1780	79724064
Acute respiratory distress syndrome	42.75	20.41	52	18492	44015	79681829
Peripheral swelling	42.71	20.41	6	18538	269611	79456233
Liver abscess	42.67	20.41	23	18521	6031	79719813
Renal failure	41.95	20.41	122	18422	200846	79524998
Drug intolerance	41.55	20.41	6	18538	264113	79461731
Renal impairment	41.17	20.41	104	18440	157679	79568165
Geotrichum infection	39.79	20.41	13	18531	968	79724876
Pseudomonal sepsis	39.49	20.41	22	18522	6152	79719692
Alopecia	39.47	20.41	4	18540	231351	79494493
Blast cell count increased	38.89	20.41	14	18530	1396	79724448
Dyspnoea	38.88	20.41	89	18455	856936	78868908
Pneumonia	38.63	20.41	274	18270	659972	79065872
Mucosal disorder	38.42	20.41	18	18526	3510	79722334
Cholestatic liver injury	38.30	20.41	20	18524	4921	79720923
Glomerulosclerosis	38.08	20.41	13	18531	1109	79724735
Drug ineffective for unapproved indication	38.06	20.41	53	18491	51185	79674659
Weight increased	37.86	20.41	9	18535	277377	79448467
Pleural effusion	37.11	20.41	95	18449	145167	79580677
Botulism	37.10	20.41	10	18534	381	79725463
Fungal endocarditis	36.93	20.41	11	18533	603	79725241
Enterococcus test positive	36.84	20.41	15	18529	2089	79723755
Immunosuppressant drug level increased	36.59	20.41	24	18520	9003	79716841
Acute lymphocytic leukaemia recurrent	36.27	20.41	19	18525	4705	79721139
Graft versus host disease in gastrointestinal tract	36.22	20.41	21	18523	6335	79719509
White blood cell count decreased	36.16	20.41	111	18433	188177	79537667
Pruritus	35.71	20.41	24	18520	394624	79331220
Pulmonary trichosporonosis	35.57	20.41	7	18537	62	79725782
Asthenia	35.55	20.41	40	18504	511649	79214195
Delayed graft function	35.45	20.41	17	18527	3490	79722354
Engraftment syndrome	35.18	20.41	13	18531	1396	79724448
Cystitis viral	35.09	20.41	11	18533	717	79725127
Device related sepsis	33.93	20.41	20	18524	6220	79719624
Pulmonary mucormycosis	33.77	20.41	12	18532	1153	79724691
Cytomegalovirus enterocolitis	33.15	20.41	13	18531	1642	79724202
Idiopathic pneumonia syndrome	32.93	20.41	10	18534	586	79725258
Graft versus host disease in liver	32.42	20.41	13	18531	1741	79724103
Staphylococcal bacteraemia	32.22	20.41	25	18519	12193	79713651
Plasma cell leukaemia	32.19	20.41	13	18531	1773	79724071
Mucosal erosion	32.14	20.41	14	18530	2304	79723540
Platelet transfusion	32.00	20.41	14	18530	2328	79723516
Nephropathy toxic	31.93	20.41	31	18513	20388	79705456
Graft versus host disease in skin	31.81	20.41	19	18525	6054	79719790
Depression	31.70	20.41	6	18538	216784	79509060
Drug hypersensitivity	31.59	20.41	15	18529	298901	79426943
Enterobacter infection	31.23	20.41	17	18527	4545	79721299
Hypersensitivity	31.21	20.41	11	18533	262228	79463616
Abdominal discomfort	30.74	20.41	10	18534	250717	79475127
Necrotising oesophagitis	30.51	20.41	11	18533	1102	79724742
Mixed liver injury	30.35	20.41	20	18524	7558	79718286
Chest pain	30.09	20.41	14	18530	282290	79443554
Biloma	29.83	20.41	7	18537	150	79725694
Lymphopenia	29.54	20.41	36	18508	30521	79695323
Oesophagitis	29.17	20.41	32	18512	24257	79701587
Encephalitis Japanese B	29.14	20.41	6	18538	68	79725776
Blood beta-D-glucan increased	29.11	20.41	9	18535	560	79725284
Neutropenia	28.95	20.41	138	18406	287572	79438272
Staphylococcal infection	28.85	20.41	50	18494	58245	79667599
Pseudomembranous colitis	28.63	20.41	17	18527	5357	79720487
Oral fungal infection	28.58	20.41	15	18529	3728	79722116
Adenovirus infection	28.39	20.41	20	18524	8427	79717417
Lymphocyte count decreased	28.04	20.41	44	18500	47245	79678599
Drug-induced liver injury	28.00	20.41	53	18491	66064	79659780
Fungal oesophagitis	27.97	20.41	10	18534	978	79724866
Device related infection	27.78	20.41	37	18507	34257	79691587
Rhinocerebral mucormycosis	27.30	20.41	10	18534	1048	79724796
Candida test positive	26.87	20.41	10	18534	1096	79724748
Epstein-Barr virus infection	26.61	20.41	24	18520	14392	79711452
Rash morbilliform	26.52	20.41	17	18527	6133	79719711
Contraindicated product administered	26.16	20.41	3	18541	157535	79568309
Escherichia infection	25.67	20.41	26	18518	17991	79707853
Blood urea increased	25.66	20.41	43	18501	48747	79677097
Musculoskeletal stiffness	25.25	20.41	5	18539	175003	79550841
Oral disorder	25.20	20.41	20	18524	10075	79715769
Neutropenic colitis	25.17	20.41	16	18528	5691	79720153
Blood pressure increased	24.92	20.41	9	18535	211351	79514493
Cytopenia	24.73	20.41	27	18517	20356	79705488
Brain abscess	24.71	20.41	15	18529	4921	79720923
Bacterial toxaemia	24.43	20.41	6	18538	157	79725687
Weight decreased	24.39	20.41	28	18516	355170	79370674
Back pain	24.30	20.41	21	18523	304159	79421685
Contusion	24.29	20.41	3	18541	148773	79577071
Pulmonary haemorrhage	24.25	20.41	23	18521	14694	79711150
Nausea	24.01	20.41	128	18416	957068	78768776
Anxiety	23.99	20.41	14	18530	248498	79477346
Shock	23.74	20.41	39	18505	43509	79682335
Leukaemia recurrent	23.73	20.41	12	18532	2762	79723082
Kidney fibrosis	23.72	20.41	13	18531	3522	79722322
Paraesthesia	23.51	20.41	6	18538	176317	79549527
Pancytopenia	23.26	20.41	88	18456	165657	79560187
Muscle spasms	23.19	20.41	6	18538	174724	79551120
Myocardial infarction	23.18	20.41	7	18537	184122	79541722
Toxicity to various agents	23.18	20.41	39	18505	421501	79304343
Acute febrile neutrophilic dermatosis	22.61	20.41	13	18531	3859	79721985
Aspergillus test positive	22.50	20.41	8	18536	770	79725074
Pseudomonas infection	22.47	20.41	26	18518	20877	79704967
Hypokalaemia	22.34	20.41	79	18465	143961	79581883
Gamma-glutamyltransferase increased	22.13	20.41	43	18501	54637	79671207
Acute lymphocytic leukaemia	22.08	20.41	14	18530	4955	79720889
Cryptococcal meningoencephalitis	21.65	20.41	6	18538	254	79725590
Liver disorder	21.28	20.41	50	18494	72367	79653477
Dehydration	21.24	20.41	16	18528	248171	79477673
Swelling	21.22	20.41	12	18532	216699	79509145
Gait disturbance	21.03	20.41	11	18533	207495	79518349
Reactive gastropathy	21.02	20.41	7	18537	553	79725291
Epstein-Barr virus associated lymphoproliferative disorder	21.01	20.41	12	18532	3520	79722324
Somnolence	20.97	20.41	15	18529	238966	79486878
Varicella zoster virus infection	20.96	20.41	13	18531	4428	79721416
Viral haemorrhagic cystitis	20.86	20.41	10	18534	2051	79723793
Vascular device infection	20.74	20.41	18	18526	10258	79715586
Hyperbilirubinaemia	20.70	20.41	27	18517	24491	79701353
Cerebral ventricle collapse	20.69	20.41	5	18539	122	79725722
Transplant rejection	20.60	20.41	24	18520	19413	79706431
Hypoaesthesia	20.53	20.41	8	18536	179344	79546500

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J02AX05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use
FDA CS	M0519359	Lipopeptides
FDA EPC	N0000175507	Echinocandin Antifungal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
CHEBI has role	CHEBI:35441	antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Candidiasis of the esophagus	indication	20639004	DOID:13146
Disseminated candidiasis	indication	70572005
Candidal septicemia	indication	187022007
Candidemia	indication	432261003
Prevention of Disseminated Candidiasis	indication
Candida Peritonitis	indication
Oropharyngeal Candidiasis	off-label use
Intravascular hemolysis	contraindication	15601008
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.09	acidic
pKa2	10.7	acidic
pKa3	12.91	acidic
pKa4	13.44	acidic
pKa5	13.52	acidic
pKa6	13.9	acidic
pKa7	13.91	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	June 27, 2006	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY
EQ 50MG BASE/VIAL	MYCAMINE	ASTELLAS	N021506	March 16, 2005	RX	INJECTABLE	INTRAVENOUS	June 20, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.68	CHEMBL
Beta-1,3-glucan synthase catalytic subunit 1	Enzyme		O13428_CANAX	INHIBITOR			CHEMBL	CHEMBL
Beta-1,3-glucan synthase	Unclassified		Q5AIC4_CANAL				WOMBAT-PK

External reference:

ID	Source
D02465	KEGG_DRUG
208538-73-2	SECONDARY_CAS_RN
4024920	VANDF
4024948	VANDF
C1120386	UMLSCUI
CHEBI:600520	CHEBI
CHEMBL457547	ChEMBL_ID
CHEMBL1237070	ChEMBL_ID
D000077551	MESH_DESCRIPTOR_UI
DB01141	DRUGBANK_ID
8069	INN_ID
R10H71BSWG	UNII
23666118	PUBCHEM_CID
325887	RXNORM
19567	MMSL
334346	MMSL
66902	MMSL
d05487	MMSL
010714	NDDF
010715	NDDF
416127003	SNOMEDCT_US
416233001	SNOMEDCT_US
426226002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9361	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9362	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3211	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Mycamine	HUMAN PRESCRIPTION DRUG LABEL	1	0469-3250	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-164	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-301	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-191	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-191	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-229	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-229	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-230	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-230	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	NDA	26 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6119	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6119	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6120	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6120	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	ANDA	27 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-728	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-728	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Micafungin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-729	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections